Evidence map›Paper›PMID 40837059›Full record

ReviewFrontiers in neurology2025

From imaging to intervention: emerging potential of PET biomarkers to shape therapeutic strategies for TBI-induced neurodegeneration.

Anna O Giarratana

Abstract readReview
In one paragraph

Review in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Anna O GiarratanaNuclear Medicine and Molecular Imaging Section, Department of Radiology, University of Wisconsin-Madison, Madison, WI, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This review examines the role of positron emission tomography (PET) imaging tracers in advancing our understanding of traumatic brain injury (TBI) induced neurodegeneration and the therapeutic targets they help to identify. It focuses on tracers used to evaluate post-TBI alterations in metabolism, amyloid, tau, neuroinflammation, and neurotransmitter systems. These molecular imaging tools provide critical insights into pathophysiological processes such as disrupted glucose metabolism, amyloid deposition, tau accumulation, chronic neuroinflammatory responses, and neurotransmitter dysregulation. The review also explores how these tracers, as imaging biomarkers, may guide future therapeutic strategies. Finally, it discusses the challenges and opportunities associated with integrating PET imaging into TBI diagnosis, longitudinal monitoring, and treatment planning.

Indexed as

brain injuryconcussionneurodegenerationneurotheranosticsPET/CTPET/MRIprecision medicinetraumatic brain injury (TBI)

Identifiers

PMID40837059
PMCPMC12361824

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.